See more : Grand Gulf Energy Limited (GGE.AX) Income Statement Analysis – Financial Results
Complete financial analysis of BioVie Inc. (BIVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVie Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Airports of Thailand Public Company Limited (AIPUY) Income Statement Analysis – Financial Results
- BYTE Acquisition Corp. (BYTSW) Income Statement Analysis – Financial Results
- Astra Microwave Products Limited (ASTRAMICRO.NS) Income Statement Analysis – Financial Results
- SimiGon Ltd. (SIM.L) Income Statement Analysis – Financial Results
- Bridge SaaS Limited (BGE.AX) Income Statement Analysis – Financial Results
BioVie Inc. (BIVI)
About BioVie Inc.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -229.38K | -266.84K | -237.42K | -229.38K | -229.38K | -229.38K | -229.38K | -229.38K | -51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.10M | 33.30M | 17.26M | 133.19M | 1.15M | 1.01M | 370.85K | 466.35K | 37.90K | 4.20K | 49.42K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.85M | 11.55M | 9.77M | 4.64M | 1.31M | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 70.06K |
| Other Expenses | 0.00 | 229.38M | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 212.71K | 247.08K | 0.00 |
| Operating Expenses | 31.95M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Cost & Expenses | 32.18M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Interest Income | 1.14M | 562.26K | 44.08K | 21.97K | 234.00 | 1.16K | 4.00 | 14.00 | 186.00 | 369.00 | 489.00 | 20.00 |
| Interest Expense | 2.89M | 4.30M | 2.16M | 559.46K | 4.77M | 273.00 | 40.96K | 0.00 | 81.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 369.00 | 489.00 | 70.06K |
| EBITDA | -31.95M | -45.69M | -23.68M | -137.80M | -2.46M | -2.27M | -2.14M | -1.32M | -380.81K | -233.01K | -321.90K | 20.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.18M | -45.08M | -27.25M | -138.05M | -2.69M | -2.50M | -2.37M | -1.55M | -432.03K | -233.38K | -322.39K | -70.06K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 59.05K | -5.18M | 1.17M | 7.80M | -13.98M | 52.29K | -40.96K | 222.94K | 105.00 | 369.00 | 489.00 | 20.00 |
| Income Before Tax | -32.12M | -50.26M | -26.08M | -130.25M | -16.68M | -2.44M | -2.41M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.30M | -3.29M | 559.46K | 4.77M | -51.40K | -1.00 | -222.93K | -105.00 | -369.00 | -489.00 | 20.00 |
| Net Income | -32.12M | -50.26M | -26.08M | -183.85M | -33.78M | -2.49M | -2.43M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.30 | -15.47 | -10.58 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| EPS Diluted | -7.30 | -15.50 | -10.60 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| Weighted Avg Shares Out | 4.52M | 3.24M | 2.46M | 1.24M | 492.00K | 253.00K | 76.00K | 71.00K | 69.00K | 69.00K | 69.00K | 32.98K |
| Weighted Avg Shares Out (Dil) | 4.52M | 3.25M | 2.47M | 1.24M | 492.95K | 253.96K | 76.61K | 71.51K | 69.76K | 69.77K | 69.67K | 32.98K |
Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 – BIVI
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI
NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) and certain officers. The class action, filed in the United States ("U.S.")...
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioVie Inc.(BIVI) Shareholders
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Class Action Filed Against BioVie Inc. (BIVI) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of 10(b) and...
BioVie Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
BioVie Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - BIVI
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI
NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 19, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired BioVie Inc. (“BioVie” or the...
Source: https://incomestatements.info
Category: Stock Reports